Online inquiry

IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1637MR)

This product GTTS-WQ1637MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets F10&F9 gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000504.4; NM_000133.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2159; 2158
UniProt ID P00742; P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1637MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11262MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ8259MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ13453MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ11685MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ13868MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ10282MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ7200MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ7366MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW